RxDoctor Payments Data

Nehu Patel, MD

Cardiovascular Disease · Jacksonville, FLNPI 1629030325

Payments from drug & device makers

$5,984in general payments, 2019–2025

Across 112 payments — averaging $53.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$3K
  • Novartis$438
  • Pfizer$310
  • Medtronic$234
  • Heartflow, Inc.$198
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$172
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,78447%
  • Education$3,20053%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,984 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,099,971
Medicare patients
2,717
Services billed
11,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban343$399,020
EntrestoSacubitril/Valsartan174$199,908
XareltoRivaroxaban87$88,860
Repatha SureclickEvolocumab92$88,032
FarxigaDapagliflozin Propanediol20$17,493
Praluent PenAlirocumab14$6,872
Metoprolol Succinate410$4,662
Valsartan124$2,902
Rosuvastatin Calcium225$2,829
Ezetimibe50$2,269
Atorvastatin Calcium202$2,174
Ranolazine ErRanolazine27$2,062
Losartan Potassium161$1,923
ClopidogrelClopidogrel Bisulfate113$1,519
Carvedilol166$1,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$310$399,020343 claims
NovartisEntresto$438$199,908174 claims
Johnson & JohnsonXarelto$127$88,86087 claims
AstraZenecaFarxiga$62$17,49320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →